Global leaders in autoimmune research gathered for the 2025 Colton Consortium Symposium last month, sharing breakthroughs from foundational science to translational therapies and forging collaborations to improve patient lives worldwide.
Dr. Jordan E. Axelrad, is Co-Director of the Inflammatory Bowel Disease Center at NYU Langone Health, and an Associate Professor of Medicine in the Division of Gastroenterology, Department of Medicine, […]
Associate Professor, Department of Medicine (Translational Medicine and Human Genetics), Perelman School of Medicine, University of Pennsylvania Dr. David Fajgenbaum is an Associate Professor of Medicine in the Division of […]
Assistant Professor, Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania Dr. Joseph Romano is an Assistant Professor of Informatics and Biostatistics in the Department of […]
John W. Eckman Professor of Medical Science, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania Dr. Cherry is the John W. Eckman Professor of Medical […]
Research Associate Professor, Center for Advanced Therapeutics, The Wistar Institute Dr. Troy Messick is Research Associate Professor in the Genome Regulation and Cell Signaling Program of the Ellen and Ronald […]
Associate Professor, Department of Internal Medicine (Digestive Diseases), Yale School of Medicine, Yale University Dr. David N. Assis is an Associate Professor of Medicine in the Section of Digestive Diseases […]
Building a fluorescence-based cellular screening platform to identify small molecules targeting mutant UBA1, this project addresses an acute unmet need in VEXAS syndrome and lays groundwork for broader rheumatic disease therapies.
A self-replicating RNA platform delivers anti-inflammatory cytokines directly to the airways, offering targeted local immune suppression without systemic toxicity — a mechanistically distinct approach to treating lupus lung disease.
Repurposing nuclear-penetrating autoantibodies from lupus and scleroderma patients as potent, safe inhibitors of pathogenic NETosis.
